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Abstract
Purpose of Review We pretend to highlight the most impor-
tant advances reached in the last few years in the biology of
Brucella suis and Brucella melitensis and focus attention on
new tools for the comprehension, prevention and control of
these zoonotic agents.
Recent Findings Important progress lately done in the field of
pathogenesis is presented here. This involves current studies
on proteins involved in the survival and antigenic structure of
Brucella, as well as the findings of how Brucella has achieved
modifications in order to adapt, replicate, survive and modu-
late the host´s immune system, improve the knowledge of the
performance of these bacteria.
Summary Consequently, better approaches for vaccinology
and diagnostic techniques are developed. Relevant epidemio-
logical issues based on changes in the highly conserved ge-
nome of these bacteria will be valuable tools to describe
outbreaks and disease status, along with risk factors that
would otherwise be difficult to analyze.
Keywords Brucella suis . Brucella melitensis .
Pathogenesis . Vaccines
Introduction
Brucellosis is a worldwide zoonosis, affecting humans, do-
mestic animals and wildlife. The disease is caused by a genus
Brucella which is classified as α-Protobacteria and is com-
posed of facultative intracellular bacteria. This organism has
as a major characteristic to have a predilection for the reticu-
loendothelial system and the reproductive tract. We describe
here some of the most recent relevant facts occurring due to
Brucella melitensis and Brucella suis infection [1].
The Organism
Brucella suis is an intracellular pathogen that causes reproduc-
tive losses in swine and zoonotic infections in people world-
wide. It is known that there is a certain restriction on hosts that
is affected by the different species of Brucella; there is also a
preference within the degree of biovars. For instance, B. suis
has five biovars. These different biovars usually affect differ-
ent animal hosts. B. suis biovars 1 and 3 infect pigs, and these
biovars are almost worldwide; however, biovar 2 infects pigs
and hare (Lepus europeanus), and it seems to be present main-
ly in Europe, being less pathogenic for people. Biovar 4 was
isolated from reindeer (Rangifer tarandus tarandus) and car-
ibou (Rangifer tarandus) in USA, Canada and Russia and
seen as almost not pathogenic for pigs. Finally, biovar 5 has
been isolated from rodents in Russia, and there is almost no
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report of isolation since it was isolated for the first time [2]. In
addition, this biovar was questioned as to if it belongs to
B. suis; genome studies prove that biovar 5 is a member of
this species of Brucella [3].
Brucella suis is commonly transmitted by ingestion or by
contact with fluids from infected neonates, abortions or uter-
ine discharges. Pigs usually eat remains of aborted fetuses and
placentas. The clinical manifestations of swine brucellosis are
associated with abortions in the middle of the gestation period,
stillbirth, infertility, orchitis and epididymitis in boars.
Abortions occur generally after 30 to 40 days post infection.
It was also described that doses of 104 to 105 CFU/ml are
enough to infect pigs experimentally by the conjunctival
route. Another survey describes that boars can shed 104 to
105 CFU/ml. A synthetic review of B. suis epidemiology
was described [2].
Brucella suis have particular characteristics differing from
other Brucella species when it infects swine. This bacteria
causes systemic infection with the consequence of reproduc-
tive failure, can infect pigs of all ages, and meanwhile the
transmission of the disease can be venereal as well as the
classical oral route [4].
In many countries, B. suis biovar 1 is usually isolated from
cattle, originating an important inconvenience for bovine bru-
cellosis programs due to false positive results in the serologi-
cal test for bovines, taking into account that there is not a
serological difference in cattle infected with B. abortus.
There are reports indicating that B. suis biovars 2 was iso-
lated also from cattle in Europe [5]. Brucellosis infections
have been reported also in wild (feral) swine. This condition
brings an increasing complication in the United States where
there is a high risk of infection in domestic pigs, as some
farming practices could permit the mixing of both popula-
tions. Besides, feral swine can be infected by B. abortus cre-
ating conditions for “host jumping”. This fact should be care-
fully controlled to avoid severe epidemiological consequences
[5].
Brucella melitensis is one of the most important zoonotic
agents worldwide [6].There are three known biovars of
B. melitensis, 1, 2 and 3 [5]. Goats are the classic and natural
hosts of B. melitensis and together with sheep are its preferred
hosts. The most important transmission route in susceptible
hosts is oral mucosa. B. melitensis infection in pregnant small
ruminants affects the placenta and fetus inducing late gestation
abortions in pregnant small ruminants. Goats infected with
Brucella are the main source of transmission to susceptible
animals in the flock and also to the animal handlers [1, 7].
Despite that abortion is the main clinical sign, it does not occur
in all infected goats, but these animals still shed Brucella to
the environment, becoming a major risk to other susceptible
animal species that coexist in the same environment (e.g.,
cattle and sheep)[5]. The transmission of Brucella between
different susceptible hosts can complicate the control of the
disease. Keeping cattle together with other ruminants is a risk
factor for the spread of brucellosis [8].
Camels ,which are not known to be primary hosts of
Brucella, are, however, highly susceptible to B. melitensis,
playing an importance role in the epidemiology of brucellosis
[9]. Alpine ibex (Capra ibex) and Chamois (Rupicapra
rupicapra) can be also infected and can trigger an outbreak
of brucellosis [10].
Brucella melitensis as well B. suis can be transmitted to
humans mostly as a food borne disease or, particularly, to
farmers engaged on agricultural practices. Brucellosis in
humans is a major systemic disease in which bacteria are
located within phagocytes of the reticuloendothelial system
(RES). The liver is one of the main organs of the reticuloen-
dothelial system, and it is involved in all cases of brucellosis in
both humans and animals [11]. Human brucellosis has many
clinical signs, but fever and musculoskeletal symptoms are the
most common. The mechanisms predisposing Brucella to an
osteoarticular site are not clear but these sites represent an
important niche for bacterial persistence [12]. In addition,
neutrophil recruitment is related to Brucella-induced patholo-
gies in both ruminants and in humans [13].
The Standard Immunological Diagnosis
The most widely implemented serological diagnostic
techniques are those based on the detection of antibodies
against smooth LPS, which are considered Brucella
immunodominant surface antigens.
Screening tests like Rose Bengal are broadly used world-
wide; however, the buffer plate antigen test is also used as
screening for porcine and caprine brucellosis. Another excel-
lent test is complement fixation, but it is too cumbersome and
requires very well-trained personnel. Progressively, this test
has been replaced by enzyme-linked immunosorbent assays
which brought important advantages improving sensibility,
specificity and automation. Lately, another diagnostic method
was introduced for brucellosis diagnostics: the fluorescence
polarization assay (FPA) which was demonstrated to be feasi-
ble for the diagnosis of brucellosis in pigs as well as goats.
Thus, there are enough serological methods for the diagnosis
of brucellosis but they also have some limitations [14]. As an
example, none of these tests has the ability to identify the type
of Brucella species, onset of infection, course of the disease,
or even if the animal has active disease at the time of sampling,
because antibody titers may remain high for a long period of
time after the onset of infection. In addition, REV 1 vaccinated
animals are very difficult to distinguish from truly infected
ones. Lately, the lateral flow test (LFA) was also evaluated
in several species, including ruminants; those studies claim
that LFA is more sensitive and specific than traditional
methods previously mentioned in this review and suggest
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using it as confirmatory tests. However, although it is prom-
issory, we understand that more work should be done in order
to evaluate and standardize the reagents of the test which are
allowed to be prescribed by the World Organisation for
Animal Health (OIE).
We also understand that the major challenge with these
diagnostic tests is to increase the diagnostic specificity, mainly
in places where Rev 1 vaccine, Suis 2, and/or Strain 19 are
implemented, thus, false positives results are common. To
solve this difficulty, different approaches have been applied
using different protein antigens with possibly diagnostic ac-
tivities. For example, cooper/zinc superoxide dismutase,
lumazine synthase, or BP26, are the most well-known candi-
dates; however, still none of these proteins can be standard-
ized to be an “ideal” antigen [15].
Recently, a couple of studies were done, trying to improve
the diagnosis of porcine brucellosis. An experiment demon-
strates that a skin test using a genetically defined mutant
(B. abortusΔmanBcore) results in a 100% specificity in pigs
infected with B. suis biovar 2 and also in a free herd, while
they were false positives with standard diagnostic tests [16]. In
a related study in pigs, the performance of an Indirect ELISA
with R-LPS, gel immunodiffusion, counterimmuno-electro-
phoresis, latex agglutination and indirect ELISA with OPS
free proteins in comparison with current serological tests
based in S-LPS was evaluated. Protein tests show 100% spec-
ificity, but the sensitivity was lower than 63%. However,
among S-LPS tests, gel immunodiffusion shows 68% sensi-
tivity and 100% specificity. The authors suggest that gel im-
munodiffusion could be a practical alternative to intradermal
testing [17]. Knowing that these tests need to be validated, and
probably used in determined regions, we understand that for
regions where productive animals are raised extensively and/
or the number of animals is quite large, neither the skin test nor
the gel diffusion test will be able to replace neither standard
immunoassays nor fluorescent polarization.
The Advanced Diagnostic Tests
Serological tests based on antibody detection of smooth
Brucella are the basis of ruminants as well as porcine brucel-
losis diagnosis. The high sensitivity and specificity of these
tests are the reasons for which they are chosen [18–20]. But,
Brucella spp. proteins play an important role triggering cell
mediated immune (CMI) response in the host, which is the
most relevant protection against Brucella infection.
Measurement of IFN-γ could be useful to differentiate vacci-
nated animals from truly infected ones and can be used to
monitor evolution of infected animals predicting any repro-
ductive problems [21•].
During stages of the disease, IFN-γ may shift. The varia-
tion in the presence of this cytokine in the pregnant sheep can
be correlated to the stage of the disease and the dissemination
of B. melitensis. After a first bacteremia, colonization of pla-
centa in pregnant ewe, plus the cessation of circulation in
peripheral blood, can be determinants of a decline in the pro-
duction of specific IFN-γ by blood cells. If an abortion occurs,
a second circulation of B. melitensis takes place in the infected
sheep, inducing an increase in the IFN-γ response. Moreover,
detection of IFN-γ shows infection earlier than tests based on
LPS antibodies, but it is not able to detect all infected animals,
in contrast with the classical serological tests [21•].
There are advances to investigating the properties of spe-
cific OPS epitopes in serodiagnosis related to the M epitope.
Recent structural evidence shows the existence of an M-type
of each smooth Brucella [22].
Constructions of an alternative M epitope [23, 24] with a
unique structures that does not exist in nature has been in order
to develop a diagnostic platform based on ELISA [25].
The combination of these proposed diagnostic antigens
with a vaccine that has A epitopes can potentially create a
diagnostic technique that is not adversely affected by the ap-
plication of a vaccine. The only smooth Brucella biovar that
does not possess this M epitope is B. suis biovar 2 [5].
Closely related Brucella isolates are difficult to distinguish;
meanwhile, it is not possible to distinguish them by using a
serological tests or classical bacteriology; even with PCR,
typing is not possible. The genome sequence amplification
method based on PCR is an alternative tool. The identification
of similar Brucella spp. is achievable with multiple gene se-
quence analyses, such as multi-locus sequencing (MLS) and
multi-locus variable-number tandem repeat (MLVA). These
techniques use a limited number of candidate genes and the
intraspecies relationships of B. melitensis may be difficult to
resolve. The whole genome single nucleotide polymorphisms
(SNP) based on phylogenetic analysis can help with this trou-
ble, providing higher resolution power and resolving genetic
relationships between the B. melitensis species [26••].
Whole genome SNP-based phylogenetic analysis can iden-
tify isolates, and demonstrate the phylogenetic links in
B.melitensis andB. suis in relation to the geographical origins.
Some mutations or acquisition of genome changes may be
related to bacterial adaptation to different environments or
even to a specific host [26••, 27].
MLVA has been confirmed as a useful technique to assess
B. melitensis genetic relations between isolates and the trace-
ability to enhance prevention, control and eradication of bru-
cellosis. Using similar techniques with B. suis, isolates can be
differentiated into clades despite slight differences at the ge-
nome level.B. suis contains, likeB. melitensis, sufficient poly-
morphisms for genetic analyses, such as genotypes distribu-
tion, tracing swine outbreaks, or the identification of potential
feral or domestic sources [20].
To use a large database of MLVA profiles of Brucella iso-
lates is crucial to the usefulness of MLVA as an
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epidemiological tool. MLVA has been shown to be useful in
revealing the most prevalent genotypes, distribution, circula-
tion and relatedness of Brucella isolates, mainly in endemic
areas [28–30].
The quantitative real-time PCR (qPCR) assay can be also
used as a sensitive diagnostic tool for detection of B. suis. It is
remarkable that the high sensitivity of this assay outperforms
previous PCR assays for the specific detection of B. Suis. The
specificity of this qPCR is 100% for B. suis and negative for
another Brucella spp. or another bacterium. It also can be used
as a screening method, because it is a low cost, fast and reli-
able assay for large sample pools of B. suis 1 to 4 [31, 32].
New diagnostic techniques must be evaluated to improve
the performance of the standard ones. Therefore, sensibility
and specificity, simplicity, the ability to differentiate vaccinat-
ed from infected animals, and costs are some variables to be
assessed before they can be widely implemented.
The Pathogenicity
Knowledge of genomics has led to the identification of varia-
tions in the genome of different species and strains of
Brucella, allowing understanding virulence factors and sur-
vival of bacteria in specific hosts. With techniques such as
cDNA microarrays, it is feasible to determine genome tran-
script changes of B. melitensis genes. It is predictable that the
majority of upregulated genes in the log phase cultures are
associated with growth.
Recent information describes that environmental stress re-
sistance and adaptation to intracellular life are related to the
cell envelope’s associated genes of the B. melitensis [33, 34].
There is a quorum sensing (QS) communication system
that controls the expression of certain genes, showing a reac-
tion to population density and regulating virulence determi-
nants as well [35]. There is a described inducer called acyl-
homoserinelactone that works as a signal synthesized by luxI,
affecting the operation of the transcriptional regulator LuxR.
Deletion of Brucella vjbR, a LuxR-like transcriptional regula-
tor, decreases the ability to survive in the intracellular envi-
ronment of B. melitensis (e.g., potential vaccine candidates)
[36].
We know that the pathogenic potential of B. melitensis and
B. suis mostly depends on its ability to survive within host
cells. There are proteins present in the cell envelope, which are
a virulence factor of B. melitensis that promotes survival of
bacteria in host cells such as macrophages [34, 37]. Interaction
between pathogens and hosts determines a change in gene
expression patterns in the cell envelope proteins that starts
from a cascade of events , leading either to the colonization
or the elimination of pathogens in the host [38].
When Brucella spp. makes its way through the membrane
of a host’s cells, it faces extreme environmental conditions
designed to get rid of bacteria, and it has developed strategies
to avoid the host's immune system. Brucella containing vac-
uoles (BCVs) avoid the linkage with lysosomes and can resist
in an acidified environment. They also have the ability to
interact with components of the early endosome after being
entered by the host cell [39].
There are some acquisitions that Brucella has achieved in
order to adapt, replicate, survive and modulate the host´s im-
mune system. Some of these important achievements are the
well-known VirB T4SS, a perosamine-based O antigen (asso-
ciated with intracellular replication), the ability to sequester
metal ions and the skill of interfering with the immune system
via TIR domain proteins [3].
The type IV secretion system (T4SS) is essential for the
BCV biogenesis. T4SS translocates effector proteins, which
modulate traffic through the membrane throughout the secre-
tory and endocytic pathways [40]. Brucella operates systems
to move DNA or proteins into the susceptible cells, having
these as an important role in bacterial virulence. In Brucella
spp., the VirB T4SS allows development of pathogenesis in
the generation of a niche inside the host cell and is involved in
protein translocation across the cell envelope [41, 42].
The transcriptional regulator MucR plays a key role in the
expression of T4SS, in the QS system, and it is also involved in
responses to different environmental hazards. Analysis of the
mucRmutant using RNA-seq and RT-PCR identified the genes
affected by the transcriptional regulator MucR. If the mucR
gene was deleted, the tolerance to acid is affected [43, 44].
Through RNA-seq, a genome-wide transcriptome analysis
can be performed; this helps to improve the knowledge in how
certain pathways play a key role in regulation of intracellular
adaptation.
In Brucella, T4SS transports effector molecules into the
infected cells leading to control signaling pathways, and
aiming to ensure survival for the bacteria. VirB (which con-
tains 12 open reading frames) is responsible of encoding T4SS
of Brucella, termed virB1 [44].
Almost all genes homologous to mucR are involved in the
endurance, survival and adaptation of bacteria to the host cells
[43]. The virB operon for intracellular invasion and multipli-
cation is also required by B. suis. Survival and multiplication
in macrophages or epithelial cells is affected in T4SS mutants.
We must bring up that single nucleotide polymorphism (SNP)
performed in the attenuated vaccine strain B. suis S2 shows a
mutation occurring in almost all the genes of the virB operon,
coding for a type IV secretion system (T4SS), compared with
virulent isolates [27].
In B. melitensis, activity of MucR It has been shown to
modulate lipid A core modification, and resistance to environ-
mental hardness, cationic peptides, oxidative stress and deter-
gents [45].
There is a characteristic weak immune response inBrucella
infection, possibly because of the implementation of a strategy
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to avoid recognition and control the host cells [46]. This last
strategy rises due to the pro-inflammatory responses induced
by the TIR-containing protein TcpB (TIR domain containing
protein in Brucella)/Btp1 (Brucella TIR domain containing
protein) and another characterized protein, BtpB. It was
shown that TcpB and BtpB proteins were translocated into
host cells via a T4SS-dependent pathway [47].
An important assumption of the Brucella pathogenesis can
be attributed to the number of ‘hidden’ proteins that might
allow the pathogen to elicit inflammatory responses further
suppressing host immune response [48].
An uncommon and recently description behavior of
B. melitensis is the location of the bacteria inside murine
erythrocytes after intraperitoneal inoculation. The circulation
of antibodies induced by immunization drastically reduces
blood persistence of Brucella following challenge. This inva-
sion of erythrocytes may constitute an unexpected step that
helps Brucella to avoid the host defenses. It is important to
emphasize that these red cells are not capable of endocytosis
[49].
This last paragraph is intended to highlight strategies or
abilities than are unknown about the pathogenicity of
Brucella. Much effort should be made to resolve these unan-
swered questions.
The Vaccinology
B. melitensis Rev.1 is the only vaccine that is being used for
the prevention of brucellosis in specific hosts. This vaccine
has proved to be the best candidate for prophylaxis of brucel-
losis in sheep and goats [50–53]. Unfortunately, there are
some side effects related to the use of this vaccine, like the
potential reversion of virulence, the capacity of this strain of
causing infection in humans and the streptomycin resistance
encoding information. For these reasons, vaccination with this
strain is restricted to animals [52]. To reduce these limitations,
subunit vaccines, recombinant vaccines, and new attenuated
live bacteria are being designed.
The clearance of intracellular pathogens depends on Th1-
type responses and IFN-γ. This cytokine activates macro-
phages and promotes immune-responses turning antibody re-
sponses toward protective IgG2a [54, 55]. Protection against
Brucella ssp. largely relies upon the CMI responses, which
induce microbicide actions to eradicate bacteria from intracel-
lular niche [56].
Subunits vaccines depend on the identification of antigens
that raise a protective immunity, but it is not fully known
which antigens are responsible for triggering humoral and
cellular immune responses [57].
Recombinant protein-based subunit vaccines are alterna-
tive candidates for human immunization against brucellosis
[52, 58]. The presentation of different antigens in the same
vaccine can promote a better protection than that induced with
a single one, especially choosing antigens expressed at differ-
ent moments of the life cycle of Brucella [59].
The combination of rOmp31 with rTF, for example, trig-
gers strong immune responses. The immunization of mice
with rOmp31 + rTF caused a considerable decrease of
B. melitensis colonization in mouse spleen [60].
Recombinant proteins rOmp19 and rP39 were tested as pro-
tective immunogens when administered simultaneously (rO +
rP). The cocktail protein was found to be immunogenic and
demonstrates that the multivalent proteins are more immuno-
genic than the individual ones [51]. The recombinant rO + rP
cocktail established a Th1 p redominant immune responses
both for in vitro cell culture and for in vivo mouse models [61].
The use of analytical methods based on the availability of
genomic sequences are tools that can potentially propose sub-
unit antigens more efficiently as vaccine candidates [62].
Reverse vaccinology is based on in silico genome analysis
and the identification of Brucella antigens with characteristics
such as immunogenicity or structure, requirements that are
necessary if they are to be proposed as vaccines [63].
The molecular chaperone DnaK is involved in protein fold-
ing, interaction by binding to unfolded polypeptide domains
when Brucella is under adverse conditions. This protein is
able to elicit a Th1 cellular response and confers significant
protection against B. melitensis. It is also confirmed that com-
bination of antigens generates a more important protection
compared to the immunization with a single protein, as it is
exemplified with DnaK in a cocktail with Omp31. Despite the
promising results, the protection with this candidate is lower
than with other potential subunit vaccines [64].
Another chaperon protein, RHspA, is a potential candidate
vaccine for Brucella because it elicits a specific cellular re-
sponse, produces a remarkable amount of antigen-specific
IFN- and IL-12 and gives adequate protection. This candidate
appeared to work successfully for immunization to prevent
Brucella infections, but this protective immunity is inferior
to protection in mice vaccinated with Rev-1 [65].
Brucella melitensis B115 strain, a natural rough stable
strain, has demonstrated its usefulness for immunization
against B. melitensis in the mouse model. Unfortunately, vac-
cinated animals had abortions, in a similar proportion to that
observed using Rev-1, and it was documented as a possible
occurrence of in vivo phenotype reversion phenomena (from
rough to smooth) [66].
Modified B. melitensis 16 M has been used as a vaccine
candidate with the deletion of wzt, a gene encoding the O-PS
export system ATP binding protein, becoming a Brucella of
the rough phenotype. B. melitensis 16MΔwzt is able to confer
a certain degree of protection against challenges with
B. melitensis 16M (lower than the protection generated with
Rev-1). It is noteworthy that 16MΔwzt does not induce O-PS
specific antibodies [67].
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Brucella melitensis vaccine strain M5-90, similar to
B. melitensis vaccine strain Rev.1, is mostly implemented
for immunization of sheep and goats in China. A modified
M5-90 has been used as a candidate, deleting genes associated
with virulence factors. B. melitensis strain M5-90ΔwboA in-
duced slightly higher levels of IFN- than M5-90. The wboA
gene is responsible for encoding an essential glycosyltransfer-
ase for the biosynthesis of the Brucella O antigen [68].
Another approach on trying to arrive to a potential vaccine
candidate against B. melitensis that has being used is the re-
combination of viruses carrying Brucella´s DNA.
Recombinant pseudorabies virus vaccine strain expressing
bp26 (an outer membrane protein, that is conserved and im-
munogenic in all Brucella species) of B. melitensis was gen-
erated. The spleens of mice vaccinated with recombinant virus
had strong lymphocyte proliferative response and high levels
of IFN-γ [69].
A novel influenza viral vector B. abortus (Flu-BA) has also
being tested. The Brucella proteins L7/L12 and Omp16 are
present in most species of Brucella. The Flu-BA vaccine
should be able to provide cross-protection against other
Brucella species, including B. melitensis [70].
The use of bioinformatics to predict B and T cell epitopes
and construct a recombinant multi-epitope protein (rMEP), is
a promising Brucella vaccination strategy.
In vivo tests using BALB/Cmice showed a strong humoral
immune response, indicated by specific IgG levels and with
adequate induction of Th1 and Th2 response. This vaccine
does not confer better bacterial clearance against
B. melitensis 16 M infection and generated a lower level of
protection than the commercial live vaccine [71].
Many strategies have been proposed to arrive at the ideal
vaccine against B. melitensis; none have generated protection
in similar levels as B. melitensis strain Rev-1. More studies
have to be done to achieve the replacement of the current
vaccine, despite the disadvantage of Rev-1 vaccination.
It is well known that there is lack of vaccines against infec-
tions with B. suis in most parts of the world. However, in
China there is a live attenuated B. suis strain 2 vaccine (S2)
that is used to immunize pigs and also ruminants. This fact
was considered controversial for different investigators.
Recently, this vaccine was evaluated in BALB/c mice chal-
lenged with pathogenic reference Brucella strains. The spleen
of immunized mice showed an increase on TNF-α and a rel-
atively good protection against infection to B. suis but also to
B. abortus and B. melitensis. This candidate showed low vir-
ulence as there were no bacteria recovered in spleen post vac-
cination. Brucella specific IgG was detected in vaccinated
mice, and produced IFN-γ and TNF-α conferring protection
in mice from a virulent challenge by B. melitensis M28,
B. abortus 2308 and B. suis S1330. Adverse effects, such as
clinical signs or tissue damage were not described in vaccinat-
ed animals [72].
Recently, a new study described the construction of a
novel immunogen candidate against porcine brucellosis.
A highly attenuated B. suis Delta-pgm (Δpgm) mutant
strain was described, which confers a robust protective
immune response.
B. suis Δ pgm strain provides a strong pro-inflammatory
immune response with high levels of IFN- and TNF-α, con-
sistent with strains that have shown protective properties with-
out interfering with classical serological diagnostic tests.
These results clearly demonstrate that this strain was able to
trigger a robust cellular immune response that raised a remark-
able protection against the virulent B. suis suggesting that it
could be a potential candidate for the prevention of brucellosis
in swine [73•].
Contemporary literature shows tremendous efforts
that have been done employing the most current tech-
nology available, to get a better or newer vaccines to
prevent brucellosis, however still the old fashion immu-
nogens are the only ones which are helping the world to
control this extended zoonosis.
Conclusion
A major effort to understand the biology of Brucella
melitensis and B. suis has been done in the last few years.
The chief progress toward a comprehensive understanding
of the mechanism of surviving from these fantastic bacteria
evidenced from the standard agglutination tests to the se-
quencing of the bacterial genome evidence. Modern technol-
ogy helps to understand Brucella behavior, thus, research on
traffic within cells, gene activation, precise diagnostic tools,
remarkable advances in T and B cell induced factors, and new
vaccine candidates, are continuously developed. However, we
wonder why these organisms are still causing severe disease
worldwide to animals and people. Maybe the scientific work
is not enough so far, maybe control of eradication programs
are not strong enough, but undoubtedly, scientists will contin-
ue looking for and reaching more precise diagnostic tests, safe
and efficient vaccines, and overall discover those secrets that
still these bacteria have kept hidden that allow them to pro-
voke our intellect. Very much research has been done; how-
ever, and, at this moment, brucellosis research is in progress
Brucella is waiting for us!!
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